Life Sciences Sector€¦ · Life Sciences Sector: Opportunities for Investment, Talent and...

Life Sciences SectorOpportunities for Investment, Talent and Enterprise

British Columbia Technology Sector Profile

= 20 Employees

= 2 Companies

29 Companies 443 Employees

123 Companies 1,849 Employees



Vancouver Island16% Lower Mainland

69%

Interior10%

Northern B.C.5%

Life Sciences Sector: Opportunities for Investment, Talent and Enterprise

= 20 Employees

= 2 Companies


123 Companies 1,849 Employees



Vancouver Island16% Lower Mainland

69%

Interior10%

Northern B.C.5%

i�


Message from the MinisterBritishColumbiaishometoathri�ingbiotechnologyindustry;infact,wearethefastestgrowingbiotechcentreinCanada,makingusthe7thlargestinNorthAmerica.

Weha�ebuiltourindustrybyin�estinginworld-classresearchinstitutionsandbyde�elopingworld-classtalent.O�erthepastfewyearsweha�ein�estedo�er$�.5billioninourscienceinfrastructure.Mostrecently,weha�epro�ided$�72millionforanewLifeSciencesCentreattheUni�ersityofBritishColumbia,and$25millionfortheCentreforDrugResearchandDe�elopmenttohelpresearcherscollaborate,refinetheirdisco�eriesandde�elopthemforcommercialuse.

Inadditiontoourcommitmenttode�elopinginfrastructureandtalent,BritishColumbiaoffersoneofthemostprogressi�eandcost-effecti�eR&Den�ironmentsinNorthAmerica,offeringspecifictaxad�antagestolifesciencecompanies.Thisinturnhasgi�enusoneofthebestreturnsonin�estmentperresearchdollarinNorthAmerica.

WitheasyaccesstomarketsinAsia,EuropeandtheU.S.andanunparalleledqualityoflife,B.C.istrulyabeautifulplaceforlifesciencebusinessestothri�e.

ColinHansenMinisterofEconomicDe�elopment

beautifulplaceforlifesciencebusinessestothri�e.

ColinHansen

�


1 Executive Summary

2 Sector Description and Overview in British Columbia

SectorHighlights

ResearchInfrastructureandPublicIn�estment

3 Profile of 20 Largest B.C. Companies

4 Centres for Research and Innovation

5 Skilled Workforce

6 Finance and Capitalization

FiscalIncenti�es

ResearchandDe�elopmentIn�estmentTaxCredits

InternationalFinancialActi�ityAct

SmallBusinessVentureCapitalAct

EmployeeIn�estmentAct

SocialSer�iceTaxAct

7 Value Chain / Ecosystem

Endnotes

1

2

3

4

6

12

14

24

24

25

26

27

28

28

30

36

Table of Contents


Executive Summary

1

�


TheLifeSciencessectorinBritishColumbiaincludesorganizationsacti�eintheareasofbiopharmaceuticals,medicalde�ices,bio-productsandbioinformatics,amongstothers.iThesectorisdi�erseandinadditiontotheseareasitalsoincludesacti�ityinareassuchas:nanotechnology,agriculture,marine,en�ironmentalandforestry.Thisprofilefocusesonbiopharmaceuticals,whichisthelargestsub-sectorandhasthelargestconcentrationofpublicandpri�atein�estmentinresearch,companyformationandcommercialsuccess.Wherea�ailable,informationonotherareasofbiotechnologyacti�itysuchasmedicalde�iceshasbeenincluded.

InBritishColumbia,biopharmaceuticalsarethemostreadilyquantifiablecomponentofLifeSciences.Thebiopharmaceuticalssectorconsistsofupof9�companieswith2,200employees.Annualre�enuesforthebiopharmaceuticalindustryareapproximately$779millionaccordingtoa2005StatisticsCanadareport.

Incontrast,themedicalde�iceandbioproductssub-sectorsaresmaller.TheBCMedicalDe�iceTechnologiesAssociation(BCMedTech)reports63membercompaniesdirectlyin�ol�edwithde�icecreationwhiletheBCBioProductsAssociationreports25companies.

Life SciencesNumber of Companies �79(est.)

Number of Employees 2,700(est.)

Annual Revenue ($M) $800million+(est.)

2


Sector Description and Overview in British Columbia

2

3

Life Sciences Sector: Opportunities for Investment, Talent and Enterprise 2

Sector HighlightsB.C.’sbiopharmaceuticalsectorisanchoredbythreeoftheworld’sfirstprofitablebiopharmaceuticalcompanies:QLT,AngiotechandAspre�a.WorldwidesalesforQLT’sleadproductVisudyne®in2004wereUS$448million,withsalesoftheirsecondcommercialproductEligard®totalingUS$84million.Visudyne®isoneofthemostsuccessfulophthalmologyproductse�er.

Angiotech’sleadproductisthepaclitaxel-elutingcoronarystent,TAXUS®whichhasnowbeenimplantedino�eramillionpatientsworldwidewith2004salestotalingUS$2.�45billion.

ThefollowingB.C.companiesarejustafewofthosepoisedtoachie�esignificantcommercialsuccess.

CardiomePharmaCorp.:RSD�235nowknownasVernakalantiscurrentlyinPhaseIIIClinicalTrialsforatrialfibrillationandhasanestimatedmarketofo�er$2billion.

Aspre�aPharmaceuticals:CellCeptcurrentlyinPhaseIIIclinicaltrialsforlupusnephritis.

Anormed,Inc.,aB.C.-basedbiotechnologycompany,wasrecentlyacquiredforapproximately$584millionbyGenzymeCorporation.Anormedwasinlate-stagePhaseIIIClinicalTrialswithMozobil,acancertreatmentdrugwhichisexpectedtobelaunchedintheU.S.in2008,subjecttosuccessfulcompletionofitsclinicaltrialsandregulatoryappro�al.

•

•

•

•

•

•

Areas of Life Sciences Specialty/Sub-sectorsBiopharmaceuticals

MedicalDe�ices

Bioproducts

Bioinformatics

Otherareasincluding:nanotechnology,agriculture,forestry,marine,andfood.

•

•

•

•

•

4


ScientistsfromtheBCCancerAgency’sGenomeScienceCentresuccessfullysequencedtheSARS�irusin2003andtheInfluenzaA�irus(knownas“A�ianFlu”)in2004.

UBChasgenerated�20spin-offcompanies,ofwhich7�arestillacti�eandpro�ideemploymentforapproximately2,000people.Halfofthesecompaniesareinthelifesciencessector--UBCspin-offsha�ebeenhugelyinfluentialinde�elopingB.C.’sbiotechindustry.ii

SFUhasgenerated70spin-offcompanies,ofwhich45arestillacti�e.Twenty-fourpercentofthetotalspin-offcompaniesareusingtechnologiesde�elopedineitherthelifesciencesorbiomedicalengineeringareas.

B.C.isthe7thlargestbiotechnologycenterinNorthAmerica.CaliforniaisrankedaheadofB.C.withthemostcompaniesfollowedbyMassachusetts,Ontario,Quebec,NorthCarolinaandMaryland.

TheMilkenInstitute’s2006Uni�ersityTechnologyTransferandCommercializationIndexliststheUni�ersityofBritishColumbiaasthehighest-rankingCanadianinstitution,andeightho�erallinNorthAmericabehindfirstplacedMIT,theUni�ersityofCaliforniasystem(2nd),Caltech(3rd),Stanford(4th)andFlorida(5th).

BritishColumbia’spublicandpri�atebiotechfinancingfromallsourceswas$338millionU.S.in2005,representingthelargestpercentageoftotalfinancingintheCanadianindustryat33percent.Morethan69percentoftotalfundingwasfrompublicfinancingsources.

•

•

•

•

•

•

InMay2005,BCCancerAgencyspin-off,CelatorTechnologiesannouncedaUS$40millionpri�atefinancingdealtode�eloptechnologytocarryChemotherapeuticagentstodiseasesites.

Aspre�aPharmaceuticalsraised$��3minitsinitialpublicoffering,makingitthelargestIPOintheCanadianbiopharmaceuticalhistory.

Research Infrastructure and Public Investment:B.C.ishometotheMichaelSmithFoundationforHealthResearch,ago�ernmentsupportedfundingagencyforhealthresearch.Namedforthewinnerofthe�993NobelPrizeinChemistry,MichaelSmith,conductedgroundbreakingworkinDNAsequencingandgeneticengineering.Atpresent,theFoundationhasawardedfundingto�50healthresearchersand472healthresearchtraineesthroughoutB.C.’suni�ersitiesandteachinghospitalsatanin�estmentofalmost$90million.Inaddition,upto$24millionhasbeenin�estedinhealthresearchinfrastructurethroughoutthepro�ince.

TheBCCentreforDiseaseControl(BCCDC)isacomponentofthePro�incialHealthSer�icesAuthoritythatpro�idesintegrationbetweenthedeli�eryofpublichealthprogramswhilealsoattractingthebestscientistsandcliniciansforresearch.TheBCCDCincludesastate-of-the-artcontainmentle�el3facilityandmolecularlaboratorydiagnosticcapabilities,aswellascentralizedinformationmanagementsystems

RecentdatafromtheCanadianInstitutesofHealth(CIHR)pointstoanincreaseof��0percentinfundingtowardsB.C.healthresearchfromfederalsources–thelargestincreaseanywhereinCanada.

•

•

•

•

•

2


5

The$95million,23�,000sq.ft.BCCancerResearchCentrewascompletedinthefallof2004.Thefacilityhasthecapacitytohouseupto600scientificandmedicalpersonnel,andwillbringBCCancerAgencyresearchscientiststogetherinonelocation.Afurther�25,000sq.ft.dedicatedtofutureresearchisplannedforPhase2.

GenomeBritishColumbiaisin�estingo�er$278millionin28large-scaleresearchprojectsandfourtechnologyplatforms.Amongthoseprojectsarethefollowing:ApplicationofPharmacogenomicsforRationalChemotherapyofLungCancer,BetterBiomarkersofAcuteandChronicAllograftRejection,De�elopmentandValidationofComparati�eGenomicHybridizationArraysforClinicalUseinCancer,DissectingGeneExpressionNetworksinMammalianOrganogenesis,EfficientIdentificationandCloningofSingleGeneDeletionsintheNematodeCaenorhabditiselegansandFunctionalGenomicsforEmergingInfectiousDiseases(PREPARE)Project.

CenterforDrugResearchandDe�elopmentrecei�ed$25millionfromtheGo�ernmentofBritishColumbiain2007.CDRDbringstogetherresearchers,institutions,industryandfinancingtohelpbringad�ancesanddisco�eriestomarket.

•

•

•

6


Thefollowingtableprofilesthetwentylargestcompaniesinthebiopharmaceuticalandmedicalde�icesub-sectorsinB.C.Therankingsarebasedprimarilyonre�enuesandsecondarily,employmentiii.ThislistincludescompaniesthatareheadquarteredinB.C.,aswellasthosewithlocationsinB.C.

ManytechnologycompaniesthroughoutB.C.arepri�atelyheld;therefore,informationoncompanyre�enuesandemploymentisoftennota�ailable.Followingthelistoftwentycompaniesisatablewiththenamesofse�eralpri�ately-heldcompaniesacknowledgedbytheirindustryasbeingtechnologyleaders.

Profile of 20 Largest B.C. Companies

3

7

Life Sciences Sector: Opportunities for Investment, Talent and Enterprise 3Rank Company Revenue

(Most recently reported annual. CAN $M unless otherwise specified)

Employment Specialty Description

1 QLT Inc. www.qltinc.com

$280.9 B.C.: 210

Global: 240

Biopharmaceuticals; eye diseases, dermatological and urological conditions

QLT is engaged in the discovery, development and commercialization of therapies in the fields of opthamology and dermatology.

2 Angiotech Pharmaceuticals Inc. www.angiotech.com/

$231.8 B.C.: 73

Global: 1500

Drug-device combinations; developer of coronary stent system TAXUS.

Best known for its TAXUS Coronary Stent System, Angiotech is a specialty pharmaceutical company focused on developing and commercializing technologies that improve the performance of medical devices and the outcomes of surgical procedures.

3 Medical Imaging Group, a business unit of McKesson Provider Technologies www.mckesson.com

$214.0 B.C.: 500

Global: 639

Digital image management for hospitals and clinics: Horizon Radiology™ and Horizon Cardiology™

In 1988 was the first company to develop an electronic picture archiving and communications system (PACS) using personal computer/client server technology for ultrasound images.

4 Aspreva Pharmaceuticals www.aspreva.com

$88.7 B.C.: 63

Global: 103

Pharmaceuticals; develops and commercialized existing drug candidates for new applications

Aspreva is focused on identifying, developing and commercializing existing approved drugs and drug candidates for new indications.

5 Dragon Pharmaceuticals www.dragonpharma.com

$65.3 B.C.: n/k

Global: n/k

Generic pharmaceuticals; develops and markets therapeutic human protein drugs; markets and sells drugs in China

Three key divisions: biopharmaceutical, chemicals and bulk pharmaceuticals.

6 Forbes Medi-Tech www.forbesmedi.com/

$21.0 B.C.: 35

Global: 35

Cardiovascular disease Flagship product is Reducol for lowering Cholesterol.

8


7 StemCell Technologies www.stemcell.com/

$19.4 B.C.: 145

Global: 161

Specialized media and cell separation products

StemCell Technologies is a world leader in the development of products for stem cell biology and has worked to standardize the field through the Global Proficiency Testing Program. Combining StemCell Technologies’ industry standard reagents and a team of experts in hematopoiesis and stem cell biology, StemCell Technologies assists organizations in drug development, agrochemical production, environmental toxicant testing and research.

8 Cardiome Inc. www.cardiome.com/

$16.1 B.C.: 74

Global: 74

Drug research and development focused on cardiovascular disease

Cardiome engages in drug research and development for the cardiovascular disease therapeutic market. Cardiome has two product candidates for treatment of arterial arrhythmia; Vernakalant (iv) (intravenous dosing) and Vernakalant (oral) (oral dosing). Vernakalant (iv) has completed Phase III trials.

9 Tekmira Pharmaceuticals Corp. www.inexpharm.com/

$15.4 B.C.: 30

Global: 30

Biopharmaceuticals for the treatment of cancer

Tekmira Pharmaceuticals Corporation is a Canadian biopharmaceutical company developing and commercializing proprietary drugs and drug delivery systems to improve the treatment of cancer

10 International Newtech Development Inc. (IND Diagnostic, Inc.) www.ind.ca/

$13.1 B.C.: n/k

Global: 120

In-vitro diagnostic (IVD) test systems.

Biotechnology company specializing in research, development and manufacturing of advanced in-vitro diagnostic (IVD) test systems.

11 VSM Medtech Ltd. www.vsmmedtech.com/

$11.2 B.C.: 148

Global: 148

Neurological disorders and cardiovascular diseases.

Manufactures a family of non-invasive vital sign monitors.

12 Xenon Pharmaceuticals Inc. www.xenon-pharma.com

Est. $6.6 B.C.: 69

Global: 69

Genetics-based drug development.

Xenon Pharmaceuticals is a clinical genetics-based drug discovery and development company engaged in developing small molecule therapeutics based on the genetic causes of select metabolic, neurological and cardiovascular diseases.

Rank Company Revenue Employment Specialty Description

3


9

13 Nventa Biopharmaceutical Corporation (formerly StressGen Biopharmaceuticalnologies Corp.) www.nventacorp.com

$5.7 B.C.: n/k

Global: 27

Vaccines for the treatment of infectious diseases and cancers.

Nventa is developing innovative therapeutics for the treatment of viral infections, with a focus on diseases caused by the human papillomavirus (HPV).

14 Response Biomedical www.responsebio.com

$3.5 B.C.: 76

Global: 79

Medical point of care (POC) and on-site environmental testing.

Response Biomedical Corporation develops, manufactures and markets rapid on-site diagnostic

tests for use with its RAMP System for clinical and environmental applications.

15 Chromos Molecular Systems Inc. www.chromos.com

$3.2 B.C.: 26

Global: 27

Therapeutic products for the treatment of debilitating diseases

Chromos is a biopharmaceutical company with two drug development programs focused on inflammatory diseases and thrombotic disorders

16 Xillix Technologies Corp. www.xillix.com

$3.0 B.C.: 65

Global: 71

Medical imaging technologies for cancer detection

Founded in 1991, based on technology developed at the BC Cancer Agency.

Xillix has an extensive auto-fluorescence and multi-modal imaging portfolio of 31 issued patents and multiple pending applications in the United States, Japan and Europe.

(Navadeq Technologies Inc. has entered into an agreement to purchase certain assets of Xillix (April 2007).

17 Pyng Medical Corp. www.pyng.com

$2.8 B.C.: n/k

Global: n/k

Manufacturing and sales of emergency medical products

Pyng is a biomedical joint venture partnership created to develop and commercialize emergency medical devices.

Pyng manufactures F.A.S.T.1, an intraosseous device for military and civilian emergency applications.

Rank Company Revenue Employment Specialty Description

�0


18 Migenix Inc. www.migenix.com

$3.0 B.C.: 23

Global: 28

Drugs to treat or prevent infectious, degenerative and metabolic diseases

MIGENIX develops and commercializes drugs for the prevention and treatment of major medical diseases and certain conditions with unmet medical need. It is focused on advancing its pipeline of product candidates in the areas of infectious and degenerative diseases.

19 Wex Pharmaceuticals Inc. www.wextech.ca

$0.6 B.C.: 90

Global: 90

Drug products for the management of pain

Wex is focused on the development and commercialization of innovative drug products, primarily for pain management. WEX’s lead compound, Tetrodotoxin, a sodium channel blocker, is the platform for the Company’s development of a portfolio of proprietary products in the field of analgesia, drug addiction withdrawal treatment, and local anaesthesia.

20 AnorMed Inc. www.genzyme.com

$0.3 B.C.: 137

Global: 137

Hematology, human immunodeficiency virus (HIV) and oncology

AnorMED is a biopharmaceutical company that focuses on discovery, development, and commercialization of therapeutics in hematology, oncology, and HIV. Its leading product candidate is MOZOBIL, currently in Phase III studies in cancer patients undergoing stem cell transplants.

In November 2006, Genzyme Corporation, based in Cambridge, MA, acquired AnorMED for US$584 million and is conducting two separate Phase III trials for MOZOBIL.

3Rank Company Revenue Employment Specialty Description


��

Privately held Life Sciences companies(namescompiledbyPwCinconjunctionwithindustryassociationsandotherrelatedsources)

Company Area of Technology Website

Oncogenex™ Technologies, Inc. De�elopmentandcommercializationofcancertherapies www.oncogenex.ca

Neuromed Pharmaceuticals, Inc. De�elopingthenextgenerationchronicpaindrugs www.neuromed.com

Inflazyme Pharmaceuticals, Ltd. De�elopingmedicalbreakthroughstotransformtheli�esofpatientswithrespiratoryandinflammatorydiseases

www.inflazyme.com

Celator Pharmaceuticals, Inc. De�elopingnewandmoreeffecti�etherapiestotreatcancer www.celatorpharma.com

Ondine Biopharma Corporation De�elopinganinno�ati�elaser-acti�atedapproachtobroad-spectrumdisinfection

http://ondinebiopharma.com

Abgenix, Inc.(recently acquired by AMGEN)

De�elopingandmanufacturinghumantherapeuticantibodiesforthetreatmentofcolorectalcancer.

www.amgen.com

Farabloc Development Corp. De�elopedandmanufacturingapainmanagementsolutionforamputeerelatedphantompain

www.farabloc.com

InnerVision Medical Technologies De�elopmentandcommercializationofanultrahighresolution,instant-capture,acousticbasedimagingsystem

www.innermed.com

Millennium Technology Inc. (MTI) De�elopment,manufactureandsaleofMagneticResonanceImaging(MRI)systemstotheglobalhealthcarecommunity.

www.millennium.ca

Chromos Molecular Systems, Inc. De�elopingprogramsfocusedoninflammatorydiseasesandthromboticdisorders

www.chromos.com

�2


Centres for Research and Innovation

4

TheLifeSciencesSectorinB.C.ishometoanumberofworldleadingresearchfacilities.Thephysicalinfrastructureismadeupofresearchfacilitiesatouruni�ersities,researchlabs,fundingagencies,hospitalsandothersupportfacilities.AsampleofB.C.’sinfrastructureisbelow.

Sector Infrastructure BC Centre for Disease Control(BCDC)

www.bccdc.org/ TheBCCDCincludesstateoftheartcontainmentle�el3facilitiesandmoleculardiagnosticcapabilities,aswellascentralizedinformationmanagementsystems.

Michael Smith Genome Sciences Centre (BC Cancer Agency)

www.bcgsc.ca/ Thefirsthigh-throughputgenesequencingcentreinCanadathatisdedicatedtocancerresearch.

Trev & Joyce Deeley Research Centre (BC Cancer Agency)

www.bccrc.ca/drc/index.html

Studiestheimmunesystem’sresponsetocancerandhoststheTumorTissueRepositorywhichpro�idespatientspecimensforbasicandclinicalstudies.

Terry Fox Laboratory (BC Cancer Agency)

www.bccrc.ca/tfl/ Multidisciplinaryresearchincancerdiagnosisandtreatment.

Biomedical Research Centre (UBC)

www.brc.ubc.ca/brc/

Conductsmulti-disciplinaryresearchonthebody’sprocessestodefendagainstmicrobesandcancer,aswellasprocessestorepairtissues.FacilitiesincludetheUBCMulti-userFlowCytometry(FACS)Facility,UBCTransgenicFacility,andtheCollaborati�eFacilityforProteomics.

Center for Drug Research and Development

www.cdrd.ca


�3

Michael Smith Biotechnology Labs (UBC)

www.michaelsmith.ubc.ca/

Canada’sfirstinterdisciplinarybiotechnologyunit,foundedin�987,whichfocusesonhuman/animalmoleculargenetics,fermentationandbio-processengineering,plantandforestrymoleculargeneticsandbioinformatics.

Brain Research Centre (UBC)

www.brain.ubc.ca/

Anindependentresearchfacilitywitho�er�75in�estigatorsengagedinmulti-disciplinaryneuroscienceresearch.CorefacilitiesincludethePeptideArrayFacilityandtheLenti�irusFacility.

James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research (UBC)

www.icapture.ubc.ca/home.shtml

LocatedatSt.Paul’sHospital,theiCAPTURECentrehasfourcoreareas;molecularphenotyping,ultrastructuralimaging,dynamiccellularimagingandbiophysics,andorganpathophysiologyandimaging.TheCentreusesad�ancedcomputingtoidentifylinksbetweengeneticinformation,clinicaldataandphenotypicdata.

Centre for Molecular Medicine and Therapeutics (CMMT) UBC

www.cmmt.ubc.ca/

Conductsresearchonthedeterminationandcontrolofgeneticsusceptibilitytodisease.TheCMMThascorefacilitiesinthefollowingareas:bioinformatics,transgenics,genotyping,BioAnalyzer,andDNAsequencing.

Canadian Bioinformatics Resource (BCIT)

www.bcit.ca/appliedresearch/gait/projects/cbri.shtml

Canada’sfirstdedicatedindustry-orientedbioinformaticstrainingfacility,jointlyestablishedbytheNationalResearchCouncil,BCIT,andVitesseCanada.

Bioinformatics at Simon Fraser University (SFU)

www.bioinformatics.sfu.ca/

Offeringtrainingandresearchinbioinformatics,facultyincludes,Dr.Da�idBaillie,aCRCChairinGenomicsintheDepartmentofMolecularBiologyandBiochemistry(MBB),andDr.FionaBrinkman,listedbyMITTechnologyRe�iewsasoneoftheworlds“topyounginno�ators”,andin�ol�edinanumberofmicrobialpathogenbioinformaticsprojects.

University of Victoria Genome BC Proteomics Centre

www.proteincentre.com/

TheUni�ersityofVictoriaProteomicsCentrehasbeeninoperationsince200�andissupportedbycollaborati�erelationshipswithGenomeBCandGenomePrairie.Baseduponacostreco�eryfinancingmodel,theProteomicsCentrepro�idesanarrayofcomputer-basedanalyticalser�ices.

�4


Skilled Workforce

5

Thenumberofgraduatestudentsisoftenconsideredindicati�eoftheskillle�elanddepthofknowledgeandexperienceinaregion.ThefollowingtableillustratesthenumberofgraduatestudentsenrolledinscienceprogramsinB.C.uni�ersitiesfrom200�-2002to2005-2006.Inaddition,thissectionpro�idesinformationonsomeofB.C.’sresearchacti�ities.

�5


Number of Graduate Students Enrolled in British Columbia Universities

Graduate Students 2005/06 2004/05 2003/04 2002/03 2001/02

MasterofEngineering �29 �43 �66 �95 �77

MasterofAppliedScience 586 632 609 575 506

MasterofScience 2,080 2,074 �,894 �,894 �,794

MasterofHealthScience 28 32 28 3� 35

MasterofHealthAdministration 56 63 67 56 47

MasterofScience/DiplomainPeriodontics 7 9 �0 �0 8

BachelorofAppliedScience/MasterofEngineering 9 8 6 7 �0

Source: The University Presidents’ Council of British Columbia (TUPC). Data are as of September 2006.

Number of Undergraduate Students Enrolled in British Columbia Universities

Undergraduate Students 2005/06 2004/05 2003/04 2002/03 2001/02

BachelorofAppliedScience 3,883 3,623 3,387 3,062 2,8�3

BachelorofEngineering 764 770 777 73� 720

BachelorofMedicalLaboratoryScience 33 25 25 �3 �8

BachelorofScience �6,0�8 �5,58� �5,382 �4,4992 �4,7�4

BachelorofScience(TechBC) - 726 542 233 -

Source: The University Presidents’ Council of British Columbia (TUPC). Data are as of September 2006.

�6


Research Chairs CanadaResearchChairsmaybeeitherTier�orTier2.Tier�Chairsareawardedtooutstandingresearchersrecognizedbytheirpeersasworldleadersintheirrespecti�eresearcharea.Thesechairsarerenewable,andtheresearcher’suni�ersityrecei�es$200,000annuallyforse�enyears.Tier2Chairsareawardedtoemergingresearchersrecognizedbytheirpeersaspotentialworldleadersintheirareaofresearch.Tier2Chairsarerenewableonce,andtheresearcher’suni�ersityrecei�es$�00,000annuallyforfi�eyears.

Research Strengths – Number of Research Chairs

Canada Research Chairs in Life SciencesTier� 25Tier2 34NSERCResearchChairs 3LeadingEdgeEndowmentFundChairs 4LeadingEdgeEndowmentFund-In�itedProposals 5

Thefollowingliststhetitlesoftheresearchchairsidentifiedintheabo�etable.

5


�7

Titles Canada Research Chairs

Research Chair Title Year Awarded

Research Chair Department School

Tier� Biodi�ersityandSystematicsMay�,2003

WayneP.Maddison ZoologyandBotany UBC

BiotechnologyandGenomics-NeurobiologyJune�,2005

TerranceP.Snutch Psychiatry,Zoology UBC

BrainDe�elopmentNo�ember�,200�

MaxS.Cynader OphthalmologyandVisualSciences

BrainResearchCentre

CNSDisordersJanuary�,200�

A.JonStoessl Medicine UBC

GapJunctionsandDiseaseMarch�,2003

ChristianC.GNaus CellularandPhysiologicalSciences

UBC

GenomicsandMolecularBiologyJanuary�,2004

BenF.Koop Biology UVIC

Genomics/InformaticsNo�ember�,200�

Da�idL.Baillie MolecularBiologyandBiochemistry

SFU

HumanGeneticsandMolecularMedicineJanuary�,200�

MichaelR.Hayden MedicalGenetics

ImmunologyJanuary�,200�

JohnSchrader Medicine,MicrobiologyandImmunology,PathologyandLaboratoryMedicine

UBC

Integrati�eAnimalPhysiologyJuly�,2005

RobertShadwick Zoology UBC

IntelligentComputerInterfaceDesignJanuary�,200�

SeptimiuE.Salcudean

ElectricalandComputerEngineering

UBC

�8

British Columbia Technology Sector Profile5MaterialsSciencesAugust�,2006

NeilBranda Chemistry SFU

MetalloproteinaseProteomicsandSystemsBiologyJanuary�,200�

ChristopherM.O�erall

OralBiologyandMedicalSciences

UBC

MolecularCardiacPhysiologyOctober�,2003

GlenTibbits Kinesiology SFU

MolecularImmunityMay�,2004

JamieK.Scott MolecularBiologyandBiochemistry

SFU

NeurobiologyJuly�,2004

AnnMarieCraig Psychiatry UBC

NeurodegenerationandProteinMisfoldingDiseaseJanuary�,2004

NeilCashman MedicineandVancou�erCoastalHealth

UBC

NeuroscienceJuly�,2003

BrianA.MacVicar Psychiatry UBC

PathogenomicsandAntimicrobialsJanuary�,200�

RobertE.WHancock MicrobiologyandImmunology

UBC

ProteasesandDiseaseOctober�,2003

DieterBromme Biochemistry UBC

Reproducti�eHealthJuly�,2004

GeoffreyHammond ObstetricsandGynaecology UBC

SurfaceBiotechnologyJuly�,200�

CharlesHaynes ChemicalandBiologicalEngineering

UBC

SyntheticOrganicChemistryOctober�,2004

MarcoCiufolini Chemistry UBC


�9

TransfusionScienceJuly�,200�

A.GrantMauk Biochemistry UBC

VisualScienceJanuary�,200�

RobertS.Molday OphthalmologyandVisualSciences,Biochemistry

UBC

Tier2 AirwayDiseaseJuly�,2004

DarrylKnight PharmacologyandTherapeutics

UBC

Alzheimer’sDiseaseJune�,2002

WeihongSong Psychiatry UBC

BacterialPathogenesisJune�,2003

ErinGaynor MicrobiologyandImmunology

UBC

BiologyofParasitesandDiseaseVectorsApril�,2002

CarlA.Lowenberger SFU

BiomaterialsJanuary�,2002

RizhiWang MetalsandMaterialEngineering

UBC

Cardio�ascularBiochemistryMay�,2003

Da�idJ.Gran�ille PathologyandLaboratoryMedicine

UBC

CellTherapiesSeptember�,2002

ClaytonA.Smith Medicine UBC

ChemicalGlycobiologyMarch�,2004

Da�idJ.E.Vocadlo Chemistry SFU

ChronicObstructi�ePulmonaryDiseaseJuly�,2004

DonD.Sin Medicine UBC

ComputationalGenomicsOctober�,2003

S.CenkSahinalp ComputingScience SFU

DrugDisco�eryOctober�,2005

AdamFrankel PharmaceuticalSciences UBC

20


Enology/YeastGenomicsOctober�,2003

Vi�ienMeasday FacultyofLandandFoodSystems

UBC

GeneticSusceptibilitytoInflammatoryAirwayDiseasesJuly�,200�

AndrewJ.Sandford Medicine UBC

GeneticsandBeha�iourJanuary�,200�renewedNo�ember�,2005

ElizabethM.Simpson MedicalGenetics UBC

GenomicImprintingJanuary�,2003

LouiseLefeb�re Ci�ilEngineering UBC

InjuryPre�entionandMobilityBiomechanicsApril�,2005

StephenRobino�itch Kinesiology SFU

MaterialsandStructuralBiologySeptember�,2003

EldonEmberly Physics SFU

MEMSandNanotechnologyforBiomedicalDe�icesApril�,2004

MuChiao MechanicalEngineering UBC

MolecularInteractionJanuary�,2003

AlisdairB.Boraston BiochemistryandMicrobiology

UVIC

MolecularNanoscienceandProteinEngineeringOctober�5,2004

HongbinLi Chemistry UBC

MolecularOncologyJanuary�,2005

SamuelAparicio PathologyandLaboratoryMedicine

UBC,BCCancerResearchcenter

MolecularPathogenesisJuly�,2006

CarolineCameron BiochemistryandMolecularBiology

UVIC

NaturalProductsChemistryOctober�,2005

SusanMurch Chemistry,EarthandEn�ironmentalSciences

UBC(Okanagan)

5


2�

NeuropharmacologyJuly�,2003

BrianCairns PharmaceuticalSciences UBC

NeuropsychologyofVisionandEyeMo�ementsSeptember�,2004

JasonBarton OphthalmologyandVisualSciences

UBC

OrganellarProteomicsOctober�,2005

LeonardFoster Biochemistry UBC

PacemakerChannelBiologyAugust�,2005

EricAccili CellularandPhysiologicalSciences

UBC

PediatricGastroenterologyJuly�,2004

BruceA.Vallance Pediatrics UBC

ProkaryoticMembraneBiologyMarch�,2004

FranckDuong Biochemistry UBC

Regenerati�eMedicineJuly�,200�

FabioRossi MedicalGeneticsSenior UBC

RetinalandEarlyEyeDe�elopmentMarch�,2005

RobertL.Chow Biology UVIC

SpinalCordBiomechanicsJuly�,200�

ThomasR.Oxland MechanicalEngineering UBC

TheoreticalBiophysicsNo�ember�,200�

Ste�enS.Plotkin PhysicsandAstronomy UBC

TransplantationJuly�,2003

MeganK.Le�ings Surgery UBC

NSERCResearchChairs

En�ironmentalContaminants,FoodSecurityandIndigenousPeoplesoftheNorthGrantrecei�edbetween2002and2005

LaurieHingManChan

CommunityHealth Uni�ersityofNorthBritishColumbia

22


PhotodynamicTechnologiesGrantrecei�edbetween�99�-2005

Da�idDolphin Chemistry UBC

ScientificInstrumentationGrantrecei�edbetween�995-2005

DonaldDouglas Chemistry UBC

LeadingEdgeEndowmentFundChairs

Dr.DonaldB.RixLeadershipChairinAboriginalEn�ironmentalHealthFebruary2006

LaurieHingManChan

CommunityHealth Uni�ersityofNorthBritishColumbia

DepressionResearchNo�ember2005

AllanYoung Psychiatry UBC

ProstateCancerResearchJuly2005

MartinGlea�e Surgery UBC

SpinalCordInjuryResearch2002

JohnStee�es Zoology,AnatomyandSurgery

UBC

5


23

TechnologyPartnershipsCanada(TPC)isaSpecialOperatingAgencyofIndustryCanadathatmakesstrategicin�estmentstosupportresearch,de�elopmentandinno�ation.Thesein�estmentsareintendedtoencouragepri�atesectorin�estmentsinresearchandde�elopment.

IntheLifeSciencessector,TPChasappro�edonecontributionof$9.8millionwhichwasawardedtoMIGENIXInc.in2004-2005.

Technology Partnerships Canada – R&D Projects (2004-2005)

Company MIGENIX Inc

Project Antibioticdrugthatmaybeeffecti�e(asshowninpreclinicaltrials)intreatinghospital-acquiredinfections

Appro�edcontribution $9.8million

TheNRCIndustrialResearchAssistanceProgram(NRC-IRAP)pro�idesarangeoftechnicalandbusinessorientedad�isoryser�icesalongwithpotentialfinancialsupporttogrowth-orientedsmall-andmedium-sizedbusinessesandhasbeenasignificantcontributorinsupportingthecommercializationoflifescienceresearch.Theprogramreliesonanextensi�enetworkofprofessionalsacrossthecountryworkingdirectlywithclientssupportinginno�ati�eresearchandthede�elopmentandcommercializationofnewproducts.In2004/05,NRC-IRAP’snearly$�30millionintotalexpendituresaidedinbuildingtheinno�ati�ecapacitiesofo�er�0,000firmswithdirectfinancialsupportdistributedacrosso�er2,500projects.

24


0

26000

52000

78000

104000

130000

2006

$62,780

2005

$121,600

2004

$91,040

2003

$67,350

5

10

15

20

Total#ofDeals 7 13 9 17

VC Investment(000s)

Equity Investment in VC Backed Companies - B.C. Life Sciences SectorThedataisbasedon�enturecapitalin�estmentsinB.C.basedLifeSciencescompaniesandallamountsarereportedinCanadiandollars.ThisdataistakenfromtheVCReporterdatabasefromThomsonFinancial.Sometransactionsmayha�eoccurredthatha�enotbeencapturedintheThomsonFinancialdatabaseormayberecordedinU.S.datasourcesiftheacquisitionwasbyaU.S.-basedfirm.

Fiscal IncentivesThefollowingtablespro�ideprograminformationforfiscalincenti�esa�ailabletoeligiblecompaniescarryingonbusinessorresidentslocatedinB.C.Alloftheincenti�eslistedaretaxcreditsa�ailablefromeitherthepro�incialorfederalgo�ernments.

Finance and Capitalization

6

* Actual VC investment is higher as the amount of some deals not known.

25


Research and Development Investment Tax CreditsCanadaandBritishColumbiaofferagenerousprogramofresearchandde�elopmenttaxcreditstosupportinno�ation.ThesecreditscanbeusedtosubstantiallyfundR&Dandare�eryattracti�etocompaniesestablishingthemsel�esinthepro�ince.

TheScientificResearch&ExperimentalDe�elopment(SR&ED)isthefederalprogramdesignedtoencouragebusinesses,includingsmallandstart-upcompanies,todoworkthatad�ancestechnologytode�elopneworimpro�edproductsorprocesses.

SR&EDpro�idescompanieswitheitherrefundableornonrefundabletaxcreditsforeligibleexpendituresincurredinCanadaforresearchandde�elopmentacti�ities.CompaniesqualifyingasaCCPC(CanadianControlledPri�ateCorporation)areeligibletorecei�ea35percentin�estmenttaxcreditonupto$2millionofqualifiedexpendituresand20%ofqualifiedexpendituresnoteligibleforthe35percentrate.NonCCPC’sareonlyeligibletorecei�etaxcreditsof20percentofqualifiedexpenditures.Allcompaniesareabletocarryforwardfederalin�estmenttaxcreditsfor20years(from2006).

Canada – Federal Scientific Research and Experimental Development (SR&ED) Policy Detailsiv

Tax Credit Qualifying Entities Tax Credit Rate Refund Rate Further Detailsv Who Qualifies?

ScientificResearch&ExperimentalDe�elopmentTaxCreditProgram(SR&ED)

QualifyingCanadianControlledPri�ateCorps.(CCPCs)

35 %ofannualexpendituresuptothresholdof$2million

+20 %ofqualifiedexpendituresnoteligibleforthe35%rate.

100 %ofITCsoncurrentexpenditurecomputedatthe35%rate

+40 %ofITCsoncapitalexpenditurescomputedatthe35%rateandofITCsofaqualifyingcorporationatthe20%rate.

TheSR&EDisarefundabletaxcredit,whichmeansthate�enifaneligiblefirmisnotprofitable,itwillstillgetacashrefundfromengaginginR&D.

Fornon-CCPCs,e�enthoughnorefundisa�ailable,theprogramallowsfirmstoreducetaxespayableforanetpositi�ecashflow.

Qualifiedresearchmustfitad�ancement,uncertaintyandcontentcriteria.

NonCCPC’s 20% N/A

Indi�iduals 20% 40%ofITCs

26


UndertheB.C.pro�incialin�estmenttaxcreditprogram,eligiblecorporationscantakea�0percenttaxcreditagainstpro�incialincometaxinadditiontorecei�ingfederalSR&EDtaxcredits.SimilartotheSR&EDprogram,CCPC’sareeligibleforrefundswhilenon-CCPC’smustapplythecreditagainsttaxespayable.

Province of British Columbia British Columbia R&D Tax Credit Policy Detailsvi

Tax Credit Qualifying Entities Tax Credit Rate Refund Rate Further Detailsv Who Qualifies?

BritishColumbiaPro�incialR&DTaxCredit

QualifyingCanadianControlledPri�ateCorps.(CCPCs)

�0percentCreditAgainstPro�incialIncomeTax

Refundable QualifyingCCPCsarerefundableonthefirst$2millionofexpenditureseligibleforSR&EDcredit.

Qualifiedresearchmustfitad�ancement,uncertainty,andcontentcriteria.

OtherCorporations Non-refundableOtherCorporationsmaycarrythetaxcreditforward�0yearsandback3years.

International Financial Activity (IFA) Act vii

B.C.’sInternational Financial Activity (IFA) ActcameintoeffectonSeptember�,2004,andpro�ideseligiblecorporationsandspecialistswitharefundonB.C.incometaxpaidonincomethatisrelatedtothecorporation’sinternationalfinancialacti�itiesconductedinB.C.TheIFA Actwasestablishedtosupportcertainbusinessacti�itiesbyessentiallyexemptingincomefromtheseacti�itiesfrompro�incialincometaxorpro�idingasignificantreductionintheeffecti�epro�incialtaxrate.

Theseacti�ities,allofwhichmustbecarriedonwithanon-residentperson,includes:makingloans,financingforeignaffiliates,factoringtradeaccountsrecei�ables,distributionoffilmandtele�isionrights,leasingproperty,capti�einsuranceacti�itiesandforeignexchangeacti�ities.Acorporationmayrecei�eanannualrefundof�00percentofthepro�incialincometaxpaidonincomeearnedfromtheseacti�ities.AnIFAspecialistiseligibletorecei�earefundofupto75percentofincometaxespaid.

Effecti�eJanuary�,2006,theIFAhasbeenexpandedtoincludetherefundofincometaxpaidonincomederi�edfromcertaintypesoflifesciencespatents�iii.Corporationsmayrecei�eanannualtaxrefunduptothelesserof$8millionand75percentofitscorporateincometaxpaidonincomethatisderi�edfrominternationalcommercializationoflifesciencespatents.

6


27

Tobeeligiblefortherefund,patentsmustha�eaprimaryclassificationnumberinaccordancewiththeInternationalPatentClassificationandnotha�eexpired.Broadclassificationsforthetypesofpatentsthatqualifyforrefundsincludethefollowing:newplantorprocessesforobtainingthem,preser�ationofbodiesofhumansoranimal,biochemistry,microbiology,in�estigationoranalyzingfood,andin�estigationoranalyzingbiologicalmaterial.Thisprogramissummarizedinthefollowingtable.

Province of British Columbia International Financial Activity (IFA) Policy Detailsix

Tax Credit Qualifying Entities Refund Rate Further Details Who Qualifies?

BritishColumbiaInternational Financial Activity Act

IncorporatedCanadiancompanieswithpermanentestablishmentsinB.C.

�00percentofpro�incialincometaxpaidonnon-lifesciencepatentacti�ity.

Lesserof$8millionand75percentofpro�incialincometaxpaidonlifesciencespatentacti�ity.

Registeredcorporationsmayclaimataxrefundonpatentacti�ityorothereligibleacti�ities(butnotboth)

MustmaintainmembershipinInternationalFinancialCentreBritishColumbiaSociety

Small Business Venture Capital Act (SBVCA)TheB.C.MinistryofEconomicDe�elopmentofferstaxcreditstoresidentin�estorstohelpsmallbusinessescarryingonprescribedacti�itiesgainaccesstoearlystageor‘seed’capitalthrough�enturecapitalprogramsoperatedundertheSmall Business Venture Capital Act (SBVCA).Prescribedacti�itiesincludemanufacturingandprocessingofgoodsinBritishColumbia,researchandde�elopmentofproprietarytechnologies,de�elopmentandoperationofadestinationtouristresortandthede�elopmentofinteracti�edigitalmediaproducts.

Theannualcapforequitycapitalin�estmentunderthisprogramis$83millionofwhich$�0millionofprogramcapitalisreser�edforin�estmentinsmallbusinessesoperatingoutsideoftheLowerMainlandand$�7millionisreser�edforin�estmentinsmallbusinessessubstantiallyengagedinthe‘newmedia’sector.

UndertheSBVCA,programin�estmentismadeeitherthroughaholdingcorporationknownasaVentureCapitalCorporation(VCC)ordirectlytoanEligibleBusinessCorporation(EBC).TheEBCTaxCreditencouragesdirectin�estmentbyin�estorsineligiblesmallbusinessesthroughoutthepro�ince.ProfessionalmanagementoftheVCCfundselectsandmanagesadi�erseportfolioofin�estmentsonbehalfofthepoolofin�estors.DetailsoftheSBVCAprogramareoutlinedinthefollowingtable.

28


Province of British Columbia Small Business Venture Capital Act Policy Details

Tax Credit Qualifying Entities Tax Credit Rate Further Details Who Qualifies?

Small Business Venture Capital Act (SBVCA)

Residentin�estorswhopro�idein�estmentcapitalintoaVCCorEBC

30percentrefundabletaxcreditxforindi�idualstoamaximumof$60,000annually.(Notrefundableforcorporationswithnomaximumlimit.)

Taxcreditisappliedfirstagainstpro�incialandfederaltaxespayable,ifany.

In�estorsmaypro�ideupto$83millionperyearinequitycapitalforin�estmentsinsmallbusiness.

Fortaxcertificatesgreaterthan$60,000,theexcesscanbecarriedforwarduptofouryears

ResidentsandcorporationswithB.C.taxespayable

TheVentureCapitalCorporation(VCC)TaxCreditencouragesin�estmentinsmallbusinessesoperatingoutsideoftheGreaterVancou�erandCapitalRegionalDistricts.

Employee Investment Act TheLabour-SponsoredEmployee Investment Actpro�idesin�estorswiththeopportunitytorecei�eapro�incialtaxcreditof�5percentandafederaltaxcreditof�5percentontheirin�estmentinthefund.Thefundsseeklong-termequityin�estmentopportunitiesincompaniesseeking‘expansion’capital.

Labour-SponsoredFundsareregisteredundertheEmployee Investment Actandareownedbyshareholderswhorelyonprofessionalmanagementtoselectin�estments.TwoLabour-SponsoredFundsthatareregisteredinthepro�inceincludeAlturaGrowthFund(EVCC)Inc.andtheWorkingOpportunityFund(EVCC)Ltd.

Social Service Tax ActTheB.C.SocialSer�iceTaxisapro�incialsalestaxof7percentle�iedonthepurchasepriceoftangiblepersonalproperty.Eligiblemanufacturerspurchasingproductionequipmentandmachinerycanapplyforanexemptionofthesalestaxxi.

6


29

Province of British Columbia B.C. Sales Tax Exemption for Equipment and Machinery Policy Detailsxii

Tax Credit Qualifying Entities Tax Exemption Rate Further Details Who Qualifies?

Social Service Tax Act

Manufacturers Exemptfrom7percentPST Productionmachineryandequipmentpurchasedorleasedbymanufacturersareexemptfromtax

Mustmeetdefinitionofmanufacturerandequipmentmustbeusedprimarilyanddirectlyinmanufactureofqualifyingtangiblepersonalproperty

30


Thefollowingtwodiagramsillustratethe�aluechain/ecosystemsfortwoLifeSciencessub-sectorsinB.C.;biopharmaceuticalsandmedicalde�ices.Organizationsthatsupportorpro�ideser�icestothesectorareplacedintothetopandmiddleofthediagramaccordingtotheirfunctionasfollows:

Industrysupportorganization,Infrastructure,Researchfacility,Specializedfinancialorganization,orEducationandhumanresourcessupportorganization.

•••••

Value Chain / Ecosystem

7


3�

Biopharmaceuticalisrepresentedinthefirst�aluechain/ecosystemdiagramthatincludesacti�itiessuchas:

Targetidentification,Drugdisco�ery,Clinicaltrials,andProductionandmanufacturing.

MedicalDe�icesareshowinthesecond�aluechain/ecosystemdiagramthatincludestheseacti�ities:

Designandde�elopment,Productionandmanufacturing,Commercializationser�ices,Supplyanddistribution,andGlobalmarketing.

••••

•••••

32

CANREG PRA InternationalRocket BuildersBioPharma Solutions

••••

Strategic Consulting Regulatory and Compliance Support

Active Pass Pharmaceuticals Allon TherapeuticsAmgenAngiotech Pharmaceuticals AnorMED IncARC PharmaceuticalsCardiome PharmaceuticalsCelator TechnologiesChemokine TherapeuticsChromos Molecular SystemsClera IncenGeneForbes Medi-tech

•••••••••••••

GeneMax iCell TherapeuticsiCo TherapeuticsInex PharmaceuticalsInimex PharmaceuticalsInflazyme PharmaceuticalsMed BioGene IncMigenix IncNetwork ImmunologyNeuromed PharmaceuticalsNovation PharmaceuticalsNventa BiopharmaceuticalsOncogenex

•••••••••••••

BRI Pharmaceutical ResearchVancouver Coastal Health Research InstituteBiofine InternationalEmergentec Business AnalyticsSyreon Corp

••

•••

Drug DiscoveryTarget Identification

Contract ManufacturingCANREGPharmEng Technology

••

PRA International• Immuno-Precise AntibodiesPepMetric TechnologiesNorthern Lipids

•••

Biopharmaceuticals Value Chain / Ecosystem

Pre-Clinical ServicesContract Research Organizations

Aska ResearchAvan BiotechAurora BiomedicalBRI Pharmaceutical ResearchCantestI.G Micromed EnvironmentalPRA InternationalPrime TrialsSyreon CorpVancouver Coastal Health Research InstituteWax-it Histology Services

•••••••••••

Clinical Services

Ondine BiopharmaPacgen BiopharmaceuticalsPanagin PharmaceuticalsPrescient NeuropharmaProtiva BiotherapeuticsProtox TherapeuticsQLT IncSirius GenomicsTwinstrand TherapeuticsWelichem BiotechWex PharmaceuticalsXenon Pharmaceuticals

••••••••••••

Research Organizations

Active Pass Pharmaceuticals Allon TherapeuticsAmgenAngiotech Pharmaceuticals AnorMED IncARC PharmaceuticalsCardiome PharmaceuticalsCelator TechnologiesChemokine TherapeuticsChromos Molecular SystemsClera IncenGeneForbes Medi-tech

•••••••••••••

GeneMax iCell TherapeuticsiCo TherapeuticsInimex PharmaceuticalsInflazyme PharmaceuticalsMed BioGene IncMigenix IncNetwork ImmunologyNeuromed PharmaceuticalsNovation PharmaceuticalsNventa BiopharmaceuticalsOncogenexOndine Biopharma

•••••••••••••

Pacgen BiopharmaceuticalsPanagin PharmaceuticalsPrescient NeuropharmaProtiva BiotherapeuticsProtox TherapeuticsQLT IncSirius GenomicsTekmira TherapeuticsWelichem BiotechWex PharmaceuticalsXenon Pharmaceuticals

•••••••••••

BCIT Health Technology Research GroupUBC University-Industry Liaison Office (UILO)SFU University-Industry Liaison Office (UILO)BC Cancer AgencyBiomedical Research Centre (UBC)Brain Research Centre (UBC)Canadian Genetic Disease NetworkCanadian HIV Trials NetworkCentre for Integrated GenomicsGenome BCiCAPTURE Centre for Cardiovascular and Pulmonary Research

•••••••••••

ICORD (Spinal Cord Research)Michael Smith Foundation for Health ResearchSARS Accelerated Vaccine InitiativeStemcell NetworkInvestigational Drug Program (BC Cancer Agency)UBC Centre for Molecular Medicine and TherapeuticsSimon Fraser UniversityUniversity of VictoriaUniversity of Northern British ColumbiaBCIT

••••••••••

33

Enabling Technologies Lobbying and Industry Support

Production and ManufacturingClinical Trials

Industry Support OrganizationsQuality Assurance

PharmEng Technology• Bioinformatics:Genologics Life Sciences Software Kinexus Bioinformatics

•MedBioGene IncZymeworks

••

Life Sciences BCBC Innovation Council

••

Allon TherapeuticsAngiotech Pharmaceuticals AnorMED IncAspreva PharmaceuticalsCardiome PharmaceuticalsCelator TechnologiesChemokine TherapeuticsDragon Pharmaceuticals IncForbes Medi-techiCo TherapeuticsInex Pharmaceuticals CorpInflazyme PharmaceuticalsMigenix Inc

•••••••••••••

Neuromed PharmaceuticalsOncoGenex TechnologiesPacGen PharmaceuticalsProtiva BiotherapeuticsProtox TherapeuticsQLT IncTwinstrand TherapeuticsUrigen Holdings Wex Pharmaceuticals

•••••••••

QLT Inc•

Industry InfrastructureBC Advantage FundsBC Angel ForumBusiness Development Bank of Canada (BDC)Discovery CapitalGrowthWorksOVP Venture PartnersPenderFund Capital Management SmartSeed Equity IncUniversity Medical Discoveries IncVancouver Angel Technology NetworkVentures West WUTIF Capital

••••••••••••

Specialized Finance Education and HR SupportACTECHCanadian Technology Human Resource BoardBioTalent CanadaSimon Fraser UniversityUniversity of VictoriaUniversity of Northern British ColumbiaUniversity of British ColumbiaBCIT

••••••••

Discovery ParksUBC University-Industry Liaison Office (UILO)SFU University-Industry Liaison Office (UILO)Vancouver Island Technology Park

••••

34

BIoLytical LaboratoriesClinotech Diagnostics and PharmaceuticalsCoolhead Technologies IncEaglePicher Medical PowerFarabloc Development CorpMcKesson Medical ImagingMillenium Technology IncMIV Therapeutics

••

••••••

Perceptronix Medical IncProgressive Health InnovationsPyng Medical Corp QDevice Medical IncSaturn Biomedical Systems IncSorin Group Canada, Mitroflow DivisionTexon TechnologiesVSM MedTech LtdXillix Technologies Corp

••••••

•••

Angiometrix IncClinotech Diagnostics and PharmaceuticalsCoolhead Technologies Creation TechnologiesDelfi Medical Innovations EaglePicher Medical PowerEIDAM Diagnostics CorporationFarabloc Development Innovatek Medical IncInternational Newtech Development

••

•••••

•••

Production and Manufacturing

Research Facilities Pacific Centre for Advanced Materials and Structures (4D Labs, SFU)BCIT Technology Centre Health Technology Research Group

••

Industry InfrastructureJack Bell Research CentreMedical Device Development Centre (MDDC)Vancouver Island Technology ParkDiscovery ParksUBC University-Industry Liaison Office (UILO)

•••••

Design and Development

Triumph CommunicationsDEQPRO Medtech Solutions

••

Strategic Consulting Regulatory and Compliance Support Contract ManufacturingWisdahl Consulting Group• Starfish Medical

Epic Biosonics IncDatrend Systems Inc

•••

Medical Devices Value Chain / Ecosystem

LifeScan Canada LtdMcKesson Medical ImagingMDMI TechnologiesMedsurge Medical CorpMillenium Technology IncOrtho ActivePerceptronix Medical IncPM DevicesPrimeLine Medical ProductsPyng Medical Corp Response BiomedicalQDevice Medical IncSaturn Biomedical Systems

•••••••••••••

Sorin Group Canada, Mitroflow DivisionTidal PhotonicsUltrasonix Medical CorpUrodynamix TechnologiesVancouver BiotechViagenX BIotechVSM MedTech LtdXillix Technologies Corp

•••••••••

SFU University-Industry Liaison Office (UILO)BC Medical Device Development Technologies Association (BC MedTech)BC BioProducts Association

••

•

35

Bowers Medical Supply Co• Tokyo Medical Services Co Ltd.•

Supply and Distribution Global Marketing

Specialized Finance BC Advantage FundsBC Angel ForumBC Discovery FundDiscovery CapitalGrowthWorksUniversity Medical Discoveries IncVancouver Angel Technology Network

•••••••

Education and HR SupportCanadian Technology Human Resource BoardBiotechnology Human Resource Council

••

Urodynamix TechnologiesMedical Ventures Corp

••

Commercialization Services

Research Facilities Pacific Centre for Advanced Materials and Structures (4D Labs, SFU)BCIT Technology Centre Health Technology Research Group

••

Contract Design and Prototyping Lobbying and Industry Support

Industry Support Organizations

Quality AssuranceBSI Management Systems Canada IncWisdahl Consulting Group

••

Form3 Design IncJdi Design IncBalbo Medical Systems

•••

Epic Biosonics IncDatrend Systems Inc

••

Life Sciences BCBC MedtechBC Innovation Council

•••

36


Endnotes

i Biotechnology can be defined as “the application of science and technology to living organisms, as well as parts, products and models thereof, to alter living or non-living materials for the production of knowledge, goods and services” (OECD, 2005).

ii University of British Columbia Public Affairs

iii Companies included as the twenty largest companies ranked the highest by 2005 revenue according to Business in Vancouver Magazine’s, Hightech British Columbia 2006, issue and by 2004 revenue according to Business in Vancouver’s, Book of Lists 2005. Annual revenues were also confirmed by reviewing the most recent annual report for each company. In cases where the annual revenue figures differed between these sources, revenues from the company’s annual report were used. The Business in Vancouver publications were also used as sources of information on employment numbers. Finally, Factiva was used to supplement revenue and employment data where that data was unavailable. Where revenues are reported in US$, they have been converted to CA$ based on the monthly average CA$/US$ exchange rate of the last month of the company’s fiscal year. Where revenues are not from a company’s annual report, the annual 2005 exchange rate is used to convert the revenues to CA$.

iv PricewaterhouseCoopers, Tax Facts and Figures for Individuals and Corporations, 2006

v Susan Ward. Don’t Miss Out on the SR&ED Tax Credit Program. From “Your Guide to Small Business Canada” available at http://sbinfocanada.about.com/od/taxinfo/a/SREDtaxcredit.htm

vi PricewaterhouseCoopers, Tax Facts and Figures for Individuals and Corporations, 2006

vii Ministry of Small Business and Revenue, Bulletin IFA 001, International Financial Activity Overview, Revised February 2006

viii Ministry of Small Business and Revenue, Bulletin IFA 002, Life Science Patents, Revised April 2006

ix PricewaterhouseCoopers Tax Facts and Figures for Individuals and Corporations, 2006

x To the extent credit is made available by the Ministry of Economic Development.

xi Ministry of Small Business and Revenue, Bulletin SST 054, Manufacturers, Revised February 2003

xii PricewaterhouseCoopers, Tax Facts and Figures for Individuals and Corporations, 2006

Research for this profile was conducted by PWC

Life Sciences Sector€¦ · Life Sciences Sector: Opportunities for Investment, Talent and...

Documents

Transcript of Life Sciences Sector€¦ · Life Sciences Sector: Opportunities for Investment, Talent and...